HYDROCHLOROTHIAZIDE; SPIRONOLACTONE - Generic Drug Details

What are the generic drug sources for hydrochlorothiazide; spironolactone and what is the scope of patent protection?

Hydrochlorothiazide; spironolactone is the generic ingredient in three branded drugs marketed by Pfizer, Ascot, Chartwell Rx, Mutual Pharm, Mylan, Purepac Pharm, Sun Pharm Industries, Superpharm, Watson Labs, Ivax Pharms, Lederle, Parke Davis, Upsher Smith, Usl Pharma, and Vangard, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound.

Summary for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

US Patents:	0
Tradenames:	3
Applicants:	15
NDAs:	18
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
DailyMed Link:	HYDROCHLOROTHIAZIDE; SPIRONOLACTONE at DailyMed

Recent Clinical Trials for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	NA
Dutch Kidney Foundation	NA
Pfizer	PHASE1

See all HYDROCHLOROTHIAZIDE; SPIRONOLACTONE clinical trials

Pharmacology for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Drug Class	Aldosterone Antagonist Thiazide Diuretic
Mechanism of Action	Aldosterone Antagonists
Physiological Effect	Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C03DA	Aldosterone antagonists
C03D	ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
C03	DIURETICS
C	Cardiovascular system

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vangard	SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	hydrochlorothiazide; spironolactone	TABLET;ORAL	087655-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sun Pharm Industries	SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; spironolactone	TABLET;ORAL	089534-001	Jul 2, 1987	AB	RX	No	No
Pfizer	ALDACTAZIDE	hydrochlorothiazide; spironolactone	TABLET;ORAL	012616-004	Dec 30, 1982	AB	RX	Yes	No
Parke Davis	SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	hydrochlorothiazide; spironolactone	TABLET;ORAL	087948-001	Feb 22, 1983		DISCN	No	No

Market Dynamics and Financial Trajectory for Hydrochlorothiazide and Spironolactone

Last updated: February 16, 2026

Hydrochlorothiazide (HCTZ)

Market Size and Use Cases

Hydrochlorothiazide (HCTZ) is a thiazide diuretic prescribed mainly for hypertension and edema. As of 2022, the global market for antihypertensive drugs, including HCTZ, was valued at approximately $50 billion, with thiazide diuretics accounting for a significant share.

Market Trends

The demand for HCTZ is driven by its low cost, established efficacy, and widespread use. Despite competition from other antihypertensives (ACE inhibitors, ARBs), HCTZ remains a first-line therapy in many regions, especially in cost-sensitive markets East Asia, Africa, and parts of Latin America.

Patent and Regulatory Landscape

HCTZ’s patent expired in the early 2000s. Generics constitute over 85% of prescriptions in the US, reflecting a highly commoditized market. Regulatory authorities, including the FDA and EMA, maintain strict quality standards for manufacturing.

Market Competition and Pricing

The market is characterized by intense price competition among generic manufacturers. Bulk manufacturing economies and regulatory compliance costs influence pricing strategies, causing prices for HCTZ to decline over the past decade.

Forecast and Financial Trajectory

Projected compounded annual growth rate (CAGR) for the HCTZ market remains modest at approximately 1.5% from 2022 to 2027, with growth constrained by market saturation and the shift to newer antihypertensive classes. Revenue for key players is expected to stabilize or decline slightly due to patent cliff effects and generic saturation.

---

Spironolactone

Market Size and Therapeutic Uses

Spironolactone is primarily used as a potassium-sparing diuretic and hormone antagonist. Its applications span heart failure, resistant hypertension, and dermatological conditions. The global market for mineralocorticoid receptor antagonists, including spironolactone, was valued at approximately $1.8 billion in 2022.

Market Trends

The drug’s use in heart failure with reduced ejection fraction (HFrEF) and resistant hypertension sustains steady demand. Off-label dermatological applications, especially for hormonal acne, widen usage. The increasing prevalence of resistant hypertension contributes to steady demand.

Patent and Regulatory Situation

Spironolactone’s patents expired globally by 2005. As a result, generic versions dominate, with most prescriptions filled by generics. Regulatory authorities emphasize quality compliance, leading to numerous approved manufacturing sites.

Market Competition and Pricing

The generic landscape results in a highly competitive market. Prices have decreased by approximately 30% over the last decade, driven by multiple producers. Pricing strategies focus on volume sales rather than margins.

Financial Outlook

The CAGR for spironolactone’s market from 2022 to 2027 is estimated at roughly 2–3%. Growth potential hinges upon new indications, evolving guidelines for heart failure, and its use in dermatology. Patent expiry limits exclusivity, affecting revenue growth.

---

Market Drivers and Challenges

Factor	Hydrochlorothiazide	Spironolactone
Key Drivers	Cost-effective antihypertensive; widespread use	Heart failure and resistant hypertension; dermatology applications
Regulatory Environment	Approvals for generics worldwide	Similar, with multiple generic suppliers
Competitive Landscape	High generic saturation; price pressures	Same, with moderate demand expansion
Price Trends	Decline over the past decade	Steady decline; potential stabilization due to new uses
Innovation and R&D	Limited, focus on formulations and quality	Similar, limited R&D, focus on new indications

---

Financial Trajectory Summary

Hydrochlorothiazide faces diminishing revenue due to market saturation and price erosion. Its revenue share in the antihypertensive segment remains steady but is likely to decline marginally over the next five years.

Spironolactone exhibits moderate growth prospects driven by expanding clinical applications. Revenue growth may accelerate if new indications or formulations gain regulatory approval.

---

Key Takeaways

• Hydrochlorothiazide’s market is mature, with declining revenues driven by generic competition and market saturation.
• Spironolactone has more growth potential, especially in heart failure and dermatology, but remains limited by its patent expiration.
• Both drugs are primarily manufactured as generics, with pricing pressures intensifying.
• Regulatory compliance and manufacturing quality standards influence market stability.
• Future growth depends on new clinical applications, regulatory changes, and market dynamics around resistant hypertension and heart failure management.

---

FAQs

1. What factors influence the market share of generic hydrochlorothiazide?
Market share is driven by pricing, manufacturing costs, regulatory approvals, and the availability of alternative antihypertensive therapies. The commoditized nature results in high competition and thin margins.

2. How do patent expiries impact spironolactone's revenue?
Patent expiries lead to generic entry, increasing competition, decreasing prices, and limiting revenue growth for branded versions. The shift to generics reduces margins for early market entrants.

3. Are there new formulations or delivery methods for these drugs?
Current markets focus on standard tablets. Few innovative delivery methods have emerged, though extended-release formulations and combination therapies are occasionally explored to improve compliance.

4. How might regulatory changes affect these markets?
Stricter quality standards could impose higher manufacturing costs. Conversely, accelerated approval pathways for new indications could stimulate market growth for spironolactone.

5. Which emerging therapies threaten the market positions of HCTZ and spironolactone?
Newer antihypertensive agents, such as SGLT2 inhibitors and novel mineralocorticoid receptor antagonists with improved safety profiles, could gradually replace traditional diuretics.

---

References

[1] MarketWatch. "Global antihypertensive drugs market size." 2022.
[2] Grand View Research. "Mineralocorticoid receptor antagonists market analysis." 2022.
[3] U.S. Food and Drug Administration. "Drug approvals and patent status." 2022.